Login to Your Account



Pharma: Clinic Roundup


Thursday, October 10, 2013
• Pfizer Inc., of New York, reported top-line results from two Phase III trials of tofacitinib, an oral Janus kinase (JAK) inhibitor being investigated to treat adults with moderate-to-severe chronic plaque psoriasis: OPT Compare (A3921080) and OPT Retreatment (A3921111).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription